| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma
|
Tsim, Selina
|
|
|
150 |
C |
p. 12-20
|
artikel
|
| 2 |
Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort
|
Chia, Puey Ling
|
|
|
150 |
C |
p. 1-8
|
artikel
|
| 3 |
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
|
Subbiah, Vivek
|
|
|
150 |
C |
p. 90-96
|
artikel
|
| 4 |
A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: A case report
|
Huang, Xiaojie
|
|
|
150 |
C |
p. 9-11
|
artikel
|
| 5 |
A reply to “MET-mutant cancer and immune checkpoint inhibitors: A large database analysis”
|
Mi, Jinye
|
|
|
150 |
C |
p. 259-260
|
artikel
|
| 6 |
A reply to “ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis”
|
Liu, Lingli
|
|
|
150 |
C |
p. 254-255
|
artikel
|
| 7 |
Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
|
Chu, Xiangling
|
|
|
150 |
C |
p. 76-82
|
artikel
|
| 8 |
Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants
|
Vickers, Alexander J.
|
|
|
150 |
C |
p. 216-220
|
artikel
|
| 9 |
Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study
|
Bishnoi, Rohit
|
|
|
150 |
C |
p. 172-177
|
artikel
|
| 10 |
Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients
|
Fusco, Nicola
|
|
|
150 |
C |
p. 53-61
|
artikel
|
| 11 |
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
|
Bersanelli, Melissa
|
|
|
150 |
C |
p. 123-131
|
artikel
|
| 12 |
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
|
Garcia-Campelo, Rosario
|
|
|
150 |
C |
p. 62-69
|
artikel
|
| 13 |
Contents
|
|
|
|
150 |
C |
p. iv-vii
|
artikel
|
| 14 |
Corrigendum to “73 - Five years of stereotactic radiotherapy for early lung cancer: Biopsy rates, outcomes and implications” [Lung Cancer, 139, 1, (January 2020) Page S31]
|
Colori, A.
|
|
|
150 |
C |
p. 261
|
artikel
|
| 15 |
Corrigendum to “Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma” [Lung Cancer 145 (2020) 158–166]
|
Yotsukura, Masaya
|
|
|
150 |
C |
p. 262
|
artikel
|
| 16 |
Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing
|
Krause, Arthur
|
|
|
150 |
C |
p. 132-138
|
artikel
|
| 17 |
Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14–skipping mutation: A series of 6 cases
|
Mayenga, Marie
|
|
|
150 |
C |
p. 21-25
|
artikel
|
| 18 |
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)
|
Faehling, Martin
|
|
|
150 |
C |
p. 114-122
|
artikel
|
| 19 |
Editorial Board
|
|
|
|
150 |
C |
p. iii
|
artikel
|
| 20 |
Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs)
|
Mirvis, Eitan
|
|
|
150 |
C |
p. 70-75
|
artikel
|
| 21 |
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer
|
Berghmans, Thierry
|
|
|
150 |
C |
p. 221-239
|
artikel
|
| 22 |
Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analysis
|
Limonnik, Vladimir
|
|
|
150 |
C |
p. 107-113
|
artikel
|
| 23 |
Homozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre
|
Marshall, Kelly
|
|
|
150 |
C |
p. 195-200
|
artikel
|
| 24 |
Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis
|
Ohashi, Kadoaki
|
|
|
150 |
C |
p. 83-89
|
artikel
|
| 25 |
Impact of histological components on selecting limited lymphadenectomy for lung adenocarcinoma ≤ 2 cm
|
Sun, Weiyan
|
|
|
150 |
C |
p. 36-43
|
artikel
|
| 26 |
Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib
|
Gu, Jiajia
|
|
|
150 |
C |
p. 26-35
|
artikel
|
| 27 |
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study
|
Cheng, Jiang-Tao
|
|
|
150 |
C |
p. 97-106
|
artikel
|
| 28 |
Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?
|
Joosten, Pieter J.M.
|
|
|
150 |
C |
p. 209-215
|
artikel
|
| 29 |
Long-term outcomes of video-assisted thoracoscopic lobectomy for clinical N1 non-small cell lung cancer: A propensity score-weighted comparison with open thoracotomy
|
Yun, Jae Kwang
|
|
|
150 |
C |
p. 201-208
|
artikel
|
| 30 |
MET-mutant cancer and immune checkpoint inhibitors: A large database analysis
|
Li, Xuanzong
|
|
|
150 |
C |
p. 256-258
|
artikel
|
| 31 |
Occult lymph node metastases in clinical N0/N1 NSCLC; A single center in-depth analysis
|
Beyaz, Ferhat
|
|
|
150 |
C |
p. 186-194
|
artikel
|
| 32 |
Oncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716
|
Danson, Sarah J.
|
|
|
150 |
C |
p. 145-151
|
artikel
|
| 33 |
Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non–small cell lung cancer previously treated with crizotinib: Results from ASCEND-6
|
Wu, Yi-Long
|
|
|
150 |
C |
p. 240-246
|
artikel
|
| 34 |
Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature
|
Hermans, B.C.M.
|
|
|
150 |
C |
p. 152-158
|
artikel
|
| 35 |
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study
|
Zeng, Jian
|
|
|
150 |
C |
p. 164-171
|
artikel
|
| 36 |
Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer
|
Voong, Khinh Ranh
|
|
|
150 |
C |
p. 249-251
|
artikel
|
| 37 |
Response to Osimertinib in a NSCLC Patient Harboring EGFR V843I Germ-Line Mutation
|
Song, Huihui
|
|
|
150 |
C |
p. 247-248
|
artikel
|
| 38 |
ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis
|
Li, Xuanzong
|
|
|
150 |
C |
p. 252-253
|
artikel
|
| 39 |
Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors
|
Zhou, Yue
|
|
|
150 |
C |
p. 178-185
|
artikel
|
| 40 |
The potential of 18F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer
|
Wang, Lihua
|
|
|
150 |
C |
p. 44-52
|
artikel
|
| 41 |
Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients
|
Li, Janice J.N.
|
|
|
150 |
C |
p. 159-163
|
artikel
|
| 42 |
Tumor-infiltrating CD8+ T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells
|
Zeng, Chenxi
|
|
|
150 |
C |
p. 139-144
|
artikel
|
Tijdschrift beschrijving